Depomed Inc

Depomed Inc. is a specialty pharmaceutical company headquartered in Newark, California. The company employs 138 people and generates $120.7 million in annual revenue. Depomed is publicly traded on the NASDAQ stock exchange under the ticker symbol DEPO. Depomed focuses on developing and commercializing pharmaceutical products in the areas of pain and neurology. They currently market three medicines for neuropathic pain and migraine through their Neurology and Pain Business. Additionally, they have a Specialty Business focused on orphan drug indications and unmet medical needs, which was recently expanded through a Cosyntropin transaction. The company's growth strategy centers around three pillars: maintaining and growing their NUCYNTA franchise through a commercialization agreement with Collegium, expanding their Neurology and Pain Business, and developing a new Specialty Business focused on underserved patient populations. Depomed is committed to identifying and licensing new products that offer enhanced therapeutic options for patients. For more information, visit Depomed's website at depomed.com.